Multiple Treatments for Non-Small Cell Lung Cancer
(ALTAIR Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new treatment combinations for individuals with metastatic non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Researchers aim to determine if these new drug combinations, including both standard and experimental medicines such as AB248 and Rilvegostomig, are safe and effective. Participants must have Stage IV NSCLC, be able to provide a tumor sample, and possess a specific type of tumor marker called PD-L1. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive potentially groundbreaking therapies.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are on medications known to cause certain heart rhythm issues or are under chronic therapy with antiplatelet agents, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research is currently examining the safety and tolerability of combining AB248 with rilvegostomig. Since this study is in its early stages, limited safety information is available for this specific combination.
For the combination of rilvegostomig with ramucirumab and chemotherapy, previous studies have explored similar treatments. These studies focus on patient responses and any side effects experienced. Because this study involves both new and standard treatments, early trials aim to determine safe dosage levels and monitor for side effects.
Both combinations are being tested in early-stage trials. The main goal is to ensure safety and find the right doses before later stages test treatment effectiveness. Reaching this phase suggests some initial confidence in safety from earlier lab or animal tests. However, more data is needed to fully understand its safety for humans.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for non-small cell lung cancer (NSCLC) because they showcase innovative approaches that differ from the standard options like surgery, radiation, and chemotherapy with agents such as cisplatin and pemetrexed. The investigational treatment AB248 is combined with rilvegostomig and targets cancer cells through a novel mechanism that may enhance the body's immune response against tumors. Meanwhile, rilvegostomig, when paired with ramucirumab and chemotherapy, is being studied for its potential to improve outcomes by leveraging its unique ability to inhibit specific growth factors in cancer cells. These combinations aim to offer more effective and tailored options for patients with both squamous and non-squamous NSCLC.
What evidence suggests that this trial's treatments could be effective for metastatic NSCLC?
Research has shown that combining the drugs AB248 and rilvegostomig may help treat non-small cell lung cancer (NSCLC). This trial will evaluate the effectiveness of this combination in some participants. Patients who previously used rilvegostomig have generally tolerated it well and experienced positive early results. Other participants in this trial will receive a combination of rilvegostomig with ramucirumab and chemotherapy, which studies suggest could benefit those with advanced NSCLC. Both drug combinations aim to enhance treatment effectiveness, and researchers remain hopeful about their potential impact. These findings offer hope that these treatments might improve outcomes for people with advanced NSCLC.12346
Are You a Good Fit for This Trial?
This trial is for individuals with advanced non-small cell lung cancer (NSCLC). Participants should be adults who can provide informed consent and are eligible to receive chemotherapy. Specific criteria may vary, so it's important to consult the study team for details.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Sub-study 1 Part A
Safety run-in to evaluate 2 or more dose levels to identify the recommended Phase 2 dose (RP2D) of AB248 in combination with rilvegostomig
Treatment - Sub-study 1 Part B
Dose expansion where participants receive AB248 in combination with rilvegostomig based on the RP2D
Treatment - Sub-study 2 Part B
Participants with non-squamous NSCLC receive SoC cisplatin or carboplatin, pemetrexed plus rilvegostomig, followed by pemetrexed plus rilvegostomig. Participants with squamous NSCLC receive SoC carboplatin plus paclitaxel or nab-paclitaxel plus rilvegostomig, followed by rilvegostomig
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AB248
- Cisplatin
- Nab-paclitaxel
- Pemetrexed
- Rilvegostomig
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology